Anixa Biosciences Inc (NASDAQ:ANIX) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Anixa Biosciences received a consensus “Hold” rating from five analysts: three Buys, one Hold, and one Sell. The average 12-month price target is $10.00, compared with the stock’s reported price of $2.77.
• The company reported quarterly EPS of -$0.08, matching analyst expectations, while analysts project a full-year EPS loss of $0.31.
• Insiders and institutional investors have shown buying interest: insiders purchased 44,188 shares over the past 90 days, while hedge funds and other institutions own 29.13% of the company.

Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) has received an average recommendation of "Hold" from the five analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $10.00.

Several analysts recently weighed in on ANIX shares. Weiss Ratings upgraded Anixa Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, June 30th. HC Wainwright reiterated a "buy" rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Zacks Research downgraded shares of Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 19th. Finally, Citigroup reaffirmed a "buy" rating on shares of Anixa Biosciences in a research note on Friday, June 12th.

Anixa Biosciences Trading Up 0.4%

Shares of NASDAQ:ANIX opened at $2.77 on Friday. The company has a market cap of $96.29 million, a price-to-earnings ratio of -8.66 and a beta of 0.51. Anixa Biosciences has a 12 month low of $2.32 and a 12 month high of $5.46. The company has a 50-day moving average price of $3.30 and a 200 day moving average price of $2.97.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings data on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). As a group, equities analysts forecast that Anixa Biosciences will post -0.31 EPS for the current year.

Insider Activity

In other Anixa Biosciences news, Director Lewis Titterton, Jr. bought 10,000 shares of the company's stock in a transaction on Thursday, September 10th. The stock was acquired at an average price of $2.73 per share, for a total transaction of $27,300.00. Following the completion of the transaction, the director directly owned 996,967 shares of the company's stock, valued at approximately $2,721,719.91. This represents a 1.01% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders purchased a total of 44,188 shares of company stock worth $138,334 in the last ninety days. 26.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Anixa Biosciences

Large investors have recently bought and sold shares of the business. Sanctuary Advisors LLC purchased a new stake in Anixa Biosciences in the second quarter worth $29,000. Northwestern Mutual Wealth Management Co. purchased a new position in Anixa Biosciences in the 2nd quarter worth about $29,000. Integrated Wealth Concepts LLC purchased a new position in Anixa Biosciences in the 2nd quarter worth about $30,000. Simplicity Wealth LLC bought a new stake in Anixa Biosciences during the 2nd quarter valued at about $34,000. Finally, NewEdge Wealth LLC purchased a new stake in Anixa Biosciences in the 2nd quarter valued at about $35,000. Hedge funds and other institutional investors own 29.13% of the company's stock.

About Anixa Biosciences

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company's research programs are designed to use the immune system to prevent or treat serious illnesses.

Anixa's cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.

In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.